Atezolizumab and pembrolizumab were approved for PD-L1-positive patients with metastatic UTUC who are ineligible for platinum-based regiments based on promising results from IMvigor-210 and KEYNOTE-052 studies [71,72]. This evidence concerns the gene CD274 and renal pelvis/ureter urothelial carcinoma.